Nivolumab for the treatment of malignant melanoma in a patient with pre-existing myasthenia gravis

A 79-year-old man with lymph node recurrence of malignant melanoma received nivolumab, an anti-programmed death 1 (PD-1) monoclonal antibody. He had pre-existing ocular myasthenia gravis (MG) and a continued small amount of corticosteroid. Grade 3 creatine phosphokinase elevation appeared after two...

Descripción completa

Detalles Bibliográficos
Autores principales: Maeda, Osamu, Yokota, Kenji, Atsuta, Naoki, Katsuno, Masahisa, Akiyama, Masashi, Ando, Yuichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nagoya University 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4767520/
https://www.ncbi.nlm.nih.gov/pubmed/27019533

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4767520/
https://www.ncbi.nlm.nih.gov/pubmed/27019533

Ejemplares similares